MDACC Study No:2008-0353 ( NCT No: NCT00826449)
Title:Phase I-II study of Dasatinib and Erlotinib in Non-Small Cell Lung Cancer
Principal Investigator:Faye M. Johnson
Treatment Agent:Dasatinib; Erlotinib
Study Status:Terminated
Study Description:The goal of the Phase I portion of this study is to find the highest tolerable
dose of the combination of dasatinib and erlotinib hydrochloride that can be
given to patients with advanced solid tumors.

The goal of the Phase II portion of this study is to learn if this combination
is effective when given to patients with non-small cell lung cancer.

The safety of this combination will be studied in both phases.
Hide details for General InformationGeneral Information

Disease Group:Lung; Solid Tumors
Phase of Study:Phase I/Phase II
Treatment Agents:Dasatinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Bristol-Myers Squibb
OSI Pharmaceuticals
Return Visit:Every 3 weeks
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Faye M. Johnson
Dept:Thoracic and Head and Neck Med
For Clinical Trial Enrollment:713-792-6363
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults